Leonard JP, et al. - Given that a median progression-free survival (PFS) of 39.4 months vs 14.1 months was achieved in patients (pts) treated with R² vs pts treated with R-placebo (PBO) among 358 pts with R/R indolent non-Hodgkin lymphoma in the AUGMENT study, researchers performed this investigation to determine how HRQoL was influenced by R² vs R-PBO. In the R² arm of the AUGMENT study, maintained HRQoL over time was reported. Treatment arms did not exhibit a clinically meaningful difference in HRQoL. HRQoL was little altered by adverse events and showed improvement following the completion or cessation of the treatment. Without compromising HRQoL, a significant PFS extension was achieved with the addition of lenalidomide to R. Post-progression HRQoL was not included in the analysis. Thus, the experts could not capture potential worsening of HRQoL attributable to disease and therapy post-progression and the influence of fewer or delayed progressions with R².